tirzepatide surmount 3 A 3-year study of in participants with obesity and prediabetes showed substantial and sustained weight reduction and decreased risk of progression to diabetes with tirzepatide, as compared with placebo. Full SURMOUNT-1 (PDF) Tirzepatide after intensive lifestyle

Effect of Subcutaneous Tirzepatide vs Placebo added to titrated insulin glargine on Glycemic Control in patients with type 2 diabetes: the SURPASS-5 Randomized Clinical Trial

It is given as a once-weekly subcutaneous injection, with doses escalated gradually under medical supervision in clinical trials

Science 1996, 273:947-977

The impact of oral semaglutide on glycemic control and weight reduction in type 2 diabetes: real-world data

Surprisingly, it was found that the Si-based agent not only relieved the intestinal symptoms associated with colitis but also the psychological symptoms such as visceral pain and discomfort

Fisher B, Costantino JP, Wickerman L, et al